Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech
Best AI Diabetic Retinopathy Screening Companies
What is AI Diabetic Retinopathy Screening?
The AI diabetic retinopathy screening market is a rapidly growing sector that utilizes artificial intelligence technology to detect and diagnose diabetic retinopathy, a common complication of diabetes that can lead to blindness if left untreated. This market offers solutions that use machine learning algorithms to analyze retinal images and identify signs of the disease, allowing for early intervention and treatment. The benefits of AI diabetic retinopathy screening include improved accuracy, speed, and cost-effectiveness compared to traditional methods. Additionally, with the rising prevalence of diabetes worldwide, there is a growing demand for these solutions in both developed and developing countries. Overall, the AI diabetic retinopathy screening market presents a promising opportunity for investors interested in healthcare technology.
Expert Collections
Market Map
Similar Markets
Do you compete within AI Diabetic Retinopathy Screening?
Reach more buyers.
Your future customers are researching their next tech solution on CB Insights. Make sure they can find you.
Top AI Diabetic Retinopathy Screening Companies
RetinAI supports eye care professionals and patients throughout the medical examination process using artificial intelligence (AI). Its solutions rely on advances in medical image analysis, ophthalmology, and machine learning. The company was founded in 2017 and is based in Bern, Switzerland.
Known Partners
Known Customers
Key People
Carlos Ciller, Melanie Oesterle-Glaeser
AEYE Health is an FDA-approved digital health company that aims to enable automated, AI-based diagnostic screening solutions for retinal imaging. AEYE Health was founded in 2018 and is based in New York, New York.
Known Partners
Subscribe, Subscribe
Key People
Subscribe, Subscribe
All Companies in AI Diabetic Retinopathy Screening
C. Light operates as a neuro-technology and artificial intelligence (AI) company. The company aims to use artificial intelligence and machine learning techniques to assess changes in eye movement as subtle as one-hundredth the size of a human hair with the help of a new tracking scanning laser ophthalmoscope device. It was founded in 2014 and is based in Medford, Massachusetts.
Key People
Subscribe
Oivi develops an online platform designed for tracking eye diseases through teleconsultation. It focuses on the early detection of Diabetic Retinopathy using a camera for retinal screening with automated image capture and diagnostics. The company aims to prevent blindness among diabetes patients by deploying an AI camera for automated retinal disease diagnostics. The company was founded in 2017 and is based in Oslo, Norway.
Key People
Subscribe, Subscribe, Subscribe
Retina is a cloud-based healthcare software designed to increase access to specialized healthcare at scale. Its software uses artificial intelligence (AI) to diagnose diseases such as diabetic retinopathy from pictures of the retina, enabling doctors to detect several diseases that can be seen in the retina in real-time. The company was founded in 2017 and is based in Santa Monica, California.
Key People
Subscribe, Subscribe, Subscribe
Vitazi.AI offers an AI platform that helps prevent diabetic blindness. It offers software that enables users to screen for diabetic retinopathy disease. The company was founded in 2021 and is based in Fort Collins, Colorado.
Key People
Subscribe
Our Methodology
The ESP matrix leverages data and analyst insight to identify and rank leading private-market companies in a given technology landscape.
What is AI Diabetic Retinopathy Screening?
The AI diabetic retinopathy screening market is a rapidly growing sector that utilizes artificial intelligence technology to detect and diagnose diabetic retinopathy, a common complication of diabetes that can lead to blindness if left untreated. This market offers solutions that use machine learning algorithms to analyze retinal images and identify signs of the disease, allowing for early intervention and treatment. The benefits of AI diabetic retinopathy screening include improved accuracy, speed, and cost-effectiveness compared to traditional methods. Additionally, with the rising prevalence of diabetes worldwide, there is a growing demand for these solutions in both developed and developing countries. Overall, the AI diabetic retinopathy screening market presents a promising opportunity for investors interested in healthcare technology.
Expert Collections
Market Map
Similar Markets
Do you compete within AI Diabetic Retinopathy Screening?
Reach more buyers.
Your future customers are researching their next tech solution on CB Insights. Make sure they can find you.